D-galactosamine based canine acute liver failure model

Hepatobiliary and Pancreatic Diseases International

Volumn 1, Issue 3, 2002, Pages 354-367

  Patzer III, John F ^a,b,c   Block, Geoffrey D ^a   Khanna, Ajai ^a   Yin, Wen Yao ^a,e   Molmenti, Ernesto ^a   Gerber, David ^a   Kramer, David J ^a,d   Scott, Victor L ^d   Aggarwal, Shushma ^d   Wagner, Robert A ^c   Fulmer, Melissa L ^a   Amiot, Bruce P ^f   Mazariegos, George V ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b University of Pittsburgh   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^f Excorp Medical Inc   (United States)

Author keywords

Acute liver failure; Biortificial liver; Canine model

Indexed keywords

ALANINE AMINOTRANSFERASE; AMMONIA; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBON DIOXIDE; DOPAMINE; GALACTOSAMINE; ISOFLURANE; LIVER ENZYME;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMMONIA BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; ARTIFACT; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BIOARTIFICIAL ORGAN; BLOOD CLOTTING DISORDER; BRAIN PERFUSION; CENTRAL VENOUS PRESSURE; CLINICAL FEATURE; CLINICAL PROTOCOL; CONTROLLED STUDY; DOG; ELECTROLYTE BALANCE; END TIDAL CARBON DIOXIDE TENSION; HISTOPATHOLOGY; INTESTINE FLORA; INTRACRANIAL PRESSURE; LETHALITY; LIVER FAILURE; LIVER NECROSIS; LUNG ARTERY PRESSURE; MALE; MICROBIAL GROWTH; MONITORING; NEUROLOGIC DISEASE; NONHUMAN; PROTHROMBIN TIME; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SURVIVAL TIME; SYSTOLIC BLOOD PRESSURE;

ANIMALS; DISEASE MODELS, ANIMAL; DOGS; GALACTOSAMINE; LIVER; LIVER FAILURE, ACUTE; MALE; SURVIVAL ANALYSIS;

EID: 12444346406     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Sielaff TD, Hu MY, Amiot B, et al. Gel-entrapment bioartificial liver therapy in galactosamine hepatitis. J Surg Res 1995;59:179-184.
2. Wantanabe FD, Mullon CJ, Hewitt WR, et al. Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. Ann Surg 1997;225:484-491.
3. Ellis AJ, Hughes RD, Wendon JA, et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996;24:1446-1451.
4. Block GD, Mazariegos GV, Khanna A, et al. Intracranial (ICP) and cerebral perfusion (CPP) pressure stabilization with a bioartificial liver assist device in a canine liver failure model [Abstract]. Artif Organs 1997;21:526.
5. Gerlach JC. Development of a hybrid liver support system: a review. Int J Artif Organs 1996;19:645-654.
6. Dixit V, Biggins S, Martin P, et al. Developmental studies with the UCLA bioartificial liver: controlled trials in animals with varying severity of liver failure [Abstract]. Artif Organs 1997;21:527.
7. Bader A, Knop E, Böker K, et al. A novel bioreactor design for in vitro reconstruction of in vivo liver characteristics. Artif Organs 1995;19:368-374.
8. Newsome PN, Plevris JN, Nelson LJ, et al. Animal models of fulminant hepatic failure: a critical evaluation. Liver Transp 2000;6:21-31.
9. Terblanche J, Hickman R, Miller D. Animal experience with support systems: are these appropriate animal models of fulminant hepatic necrosis? In: Williams R, Mung-Lyon I, eds. Artificial Liver Support. London: Pitman. 1975,163-172.
10. Terbanche J, Hickman R. Animal models of fulminant hepatic failure. Dig Dis Sci 1991;36:770-774.
11. Sielaff TD, Hu MY, Rollins MD, et al. An anesthetized model of lethal canine galactosamine fulminant hepatic failure. Hepatology 1995;21:796-804.
12. Diaz-Buxo JA, Blumenthal S, Hayes D, et al. Galactosamine-induced fulminant hepatic necrosis in unanesthetized canines. Hepatology 1997;25:950-957.
13. Lempinen M, Soyer T, Eiseman B. A new technique for preparing totally hepatectomized pigs. Surgery 1973;73:463-467.
14. Rozga J, Williams F, Ro MS, et al. Development of a bioartificial liver: properties and functions of a hollow fiber inoculated with liver cells. Hepatology 1993;17:258-265.
15. Kelly J, Koussayer T, He D, et al. An improved model of acetaminophen-induced fulminant hepatic failure in dogs. Hepatology 1992;16:60-65.
16. Maley F, Tarentino AL, McGarrahan JF, et al. The metabolism of D-galactosamine and N-acetyl-D-galactosamine in rat liver. Biochem J 1968;107:637-644.
17. Keppler D, Decker K. Studies on the mechanism of galactosamine hepatitis: accumulation of galactosamine-1-phosphate and its inhibition of UDP-glucose pyrophosphorylase. Eur J Biochem 1969;10:219-225.
18. Bekesi JG, Bekesi E, Winzler RJ. Inhibitory effect of D-galactosamine and other sugars on the biosynthesis of protein, ribonucleic acid and deoxyribonucleic acid in normal and neoplastic tissue. J Biol Chem 1969;244:3766-3772.
19. Keppler D, Rudigier J, Bischoff E. The trapping of uridine phosphates by D-galactosamine, D-glucosamine and 2-hydroxy-D-galactose. Eur J Biochem 1970;17:246-253.
20. El-Mofty SK, Scrutton MC, Serroni A, et al. Early, reversible plasma membrane injury in galactosamine-induced liver cell death. Am J Pathol 1975;79:579-595.
21. Farber JL, El-Mofty SK, Schanne FA, et al. Intracellular calcium homeostasis in galactosamine-intoxicated rat liver cells. Arch Biochem Biophys 1977; 178:617-624.
22. Schanne FA, Pfau RG, Farber JL. Galactosamine-induced cell death in primary cultures of rat hepatocytes. Am J Pathol 1980;100:25-38.
23. Keppler D, Lesch R, Reutter W, et al. Experimental hepatitis induced by D-galactosamine. Exp Mol Pathol 1968;9:279-290.
24. Blitzer BL, Waggoner JG, Jones EA, et al. A model of fulminant hepatic failure in the rabbit. Gastroenterology 1978;74:664-671.
25. Ryan CJ, Aslam M, Courtney JM. Transference of hepatic coma to normal rats from galactosamine treated donors by reverse plasma exchange. Biomater Artif Cells Artif Organs 1990;18:477-482.
26. Njoku D, Lester MJ, Gong DH, et al. Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins: association between protein acylation and hepatic injury. Anesth Analg 1997;84:173-178.
27. Ghantous HN, Fernando J, Gandolfi AJ, et al. Toxicity of halothane in guinea pig liver slices. Toxicology 1990;62:59-69.
28. van Dyke RA. Hepatic centrilobular necrosis in rats after exposure to halothane, enflurane, or isoflurane. Anesth Analg 1982;61:812-819.
29. Gil F, Fiserova-Bergerova V, Altman NH. Hepatic protection from chemical injury by isoflurane. Anesth Analg 1988;67:860-867.
30. DiNola F, Eandi M, Capra E, et al. Pharmokinetics and clinical studies of a new cephalosporin: cefamandole nafate. Minerva Med 1980;71:1515-1524.
31. Jauregui HO, Mullon CJ, Trenkler D, et al. In vivo evaluation of a hollow fiber liver assist device. Hepatology 1995;21:460-469.
32. Berthoud MC, Reilly CS. Adverse effects of general anesthetics. Drug Saf 1992;7:434-459.